Funding Opportunities

NIH Funding Opportunities

Request for Information (RFI): Development of Multivalent Vaccine Candidates For Filovirus and Lassa Fever
Notice NOT-AI-15-049 from the NIH Guide for Grants and Contracts
Wed, 29 Jul 2015 01:01:09 EST

AHRQ Announces Interest in Innovative Methods Research to Increase the Utility of Systematic Reviews
Notice NOT-HS-15-011 from the NIH Guide for Grants and Contracts
Tue, 28 Jul 2015 10:37:16 EST

Extension of Expiration Dates for AHRQ Healthcare-Associated Infection R18 and R01 Funding Opportunity Announcements (PA-12-240 and PA-12-241)
Notice NOT-HS-15-012 from the NIH Guide for Grants and Contracts
Wed, 29 Jul 2015 01:14:12 EST

Notice of Correction of the Renegotiation of Multiple PD/PI Grants Awards Policy for NINDS RFA-NS-16-001 "Research Program Award (R35)"
Notice NOT-NS-15-034 from the NIH Guide for Grants and Contracts
Tue, 28 Jul 2015 10:45:27 EST

Findings of Research Misconduct
Notice NOT-OD-15-131 from the NIH Guide for Grants and Contracts
Tue, 28 Jul 2015 11:56:06 EST

Subscribe to Receive NIH eRA Service Information
Notice NOT-OD-15-132 from the NIH Guide for Grants and Contracts
Wed, 29 Jul 2015 01:21:36 EST

Notice to Modify RFA-RM-13-006 "NIH Pioneer Award Program (DP1)" regarding the Award Budget, Biographical Sketch, and Research Strategy
Notice NOT-RM-15-015 from the NIH Guide for Grants and Contracts
Tue, 28 Jul 2015 10:56:48 EST

Notice to Modify RFA-RM-13-007 "NIH Director's New Innovator Award Program (DP2)" regarding Biographical Sketch and Research Strategy
Notice NOT-RM-15-016 from the NIH Guide for Grants and Contracts
Tue, 28 Jul 2015 11:09:12 EST

Alzheimer's Disease Translational Center for Disease Model Resources (U54)
Funding Opportunity RFA-AG-16-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish an Alzheimers Disease Translational Center for Disease Model Resources. The purpose of the Center is to: develop the next generation of rodent animal models of AD; conduct extensive characterization and clinico-pathological staging of AD animal models using translatable biomarkers; develop translatable pharmacodynamicbiomarkers for well validated therapeutic targets; develop and implement guidelines for standardized best practicesfor the rigorous preclinical testingof AD candidates; conduct preclinical testingof candidate AD therapeutics and transparent reporting.
Wed, 29 Jul 2015 01:24:34 EST

Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (T1D) (R43/R44)
Funding Opportunity RFA-DK-15-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D).
Tue, 28 Jul 2015 12:04:53 EST

Type 1 Diabetes Pathfinder Award (DP2)
Funding Opportunity RFA-DK-15-030 from the NIH Guide for Grants and Contracts. The Type 1 Diabetes Pathfinder Award (DP2) was first initiated in 2008 as part of the Strategic Plan for Type 1 Diabetes Research (http://www.T1Diabetes.nih.gov/plan).The goal is to support a small number of early stage investigators of exceptional creativity who propose bold and highly innovative new research approaches that have the potential to produce a major impact on broad, important problems in biomedical and behavioral research relevant to type 1 diabetes and its complications. The Type 1 Diabetes Pathfinder Award initiative complements ongoing efforts by NIH and its Institutes and Centers to fund early stage investigators through R01 grants, which continue to be the major sources of NIH support for early stage investigators. The research proposed need not be in a conventional biomedical or behavioral discipline but must be relevant to type 1 diabetes.
Wed, 29 Jul 2015 11:24:59 EST

Research to Advance Vaccine Safety (R01)
Funding Opportunity PA-15-312 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases, or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).
Tue, 28 Jul 2015 01:25:00 EST

Research to Advance Vaccine Safety (R21)
Funding Opportunity PA-15-313 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support research that will contribute to the overall understanding of vaccine safety. This research opportunity encourages studies that address scientific areas potentially relevant to vaccine safety such as 1) physiological and immunological responses to vaccines and vaccine components, 2) how genetic variations affect immune/physiological responses that may impact vaccine safety, 3) identification of risk factors and biological markers that may be used to assess whether there is a relationship between certain diseases or disorders and licensed vaccines, 4) creation/evaluation of statistical methodologies for analyzing data on vaccine safety, including data available from existing data sources such as passive reporting systems or healthcare databases, or 5) the application of genomic/molecular technologies and systems biology approaches to evaluate vaccine safety. This FOA aligns with the research goals and objectives outlined in the U.S. National Vaccine Plan).
Tue, 28 Jul 2015 01:25:03 EST

Discovery of Genetic Basis of Monogenic Heart, Lung, Blood, and Sleep Disorders (X01)
Funding Opportunity PAR-15-314 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to use the genome-wide sequencing capacity of the Centers for Mendelian Genomics to carry out studies of the genetic basis of Mendelian or monogenic disorders that significantly affect heart, lung, blood, and sleep (HLBS) systems.
Wed, 29 Jul 2015 12:21:41 EST